| Jeffrey Horne Tingey, DO | |
|
475 W 940 N, Provo, UT 84604-3301 | |
| (801) 357-7940 | |
| Not Available |
| Full Name | Jeffrey Horne Tingey |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 10 Years |
| Location | 475 W 940 N, Provo, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255751913 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 9498494-1204 (Utah) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
The Wall Street Journal profiles the case of a man infected with extensively drug-resistant tuberculosis (XDR-TB) who is being detained in South Texas after a "three-month odyssey through 13 countries - from his homeland of Nepal through South Asia, Brazil, Mexico, and finally into Texas - show[ing] the way in which dangerous new strains of the disease can migrate across the world unchecked."
The COVID-19 pandemic shows no signs of abating, with outbreaks in many spots still occurring across the world. From the start, health organizations and governments were focused on implementing non-pharmaceutical interventions (NPIs) in the absence of any effective antivirals or vaccines.
On the one-year anniversary of the launch of the Global Alliance for Clean Cookstoves, the U.S. made an additional financial commitment of up to $55 million, "bringing the total United States commitment to up to $105 million in the first five years," according to a State Department press release.
Direct-to-consumer advertising (DTCA) for a commonly prescribed antiplatelet drug does not appear associated with increased use, but may be associated with increased drug costs and Medicaid pharmacy expenditures, according to a report in the November 23 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem's Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS' proprietary EB66® cell line.
› Verified 4 days ago
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
The Wall Street Journal profiles the case of a man infected with extensively drug-resistant tuberculosis (XDR-TB) who is being detained in South Texas after a "three-month odyssey through 13 countries - from his homeland of Nepal through South Asia, Brazil, Mexico, and finally into Texas - show[ing] the way in which dangerous new strains of the disease can migrate across the world unchecked."
The COVID-19 pandemic shows no signs of abating, with outbreaks in many spots still occurring across the world. From the start, health organizations and governments were focused on implementing non-pharmaceutical interventions (NPIs) in the absence of any effective antivirals or vaccines.
On the one-year anniversary of the launch of the Global Alliance for Clean Cookstoves, the U.S. made an additional financial commitment of up to $55 million, "bringing the total United States commitment to up to $105 million in the first five years," according to a State Department press release.
Direct-to-consumer advertising (DTCA) for a commonly prescribed antiplatelet drug does not appear associated with increased use, but may be associated with increased drug costs and Medicaid pharmacy expenditures, according to a report in the November 23 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem's Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS' proprietary EB66® cell line.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey Horne Tingey, DO Po Box 27128, Salt Lake City, UT 84127-0128 Ph: (801) 357-7940 | Jeffrey Horne Tingey, DO 475 W 940 N, Provo, UT 84604-3301 Ph: (801) 357-7940 |
News Archive
The Wall Street Journal profiles the case of a man infected with extensively drug-resistant tuberculosis (XDR-TB) who is being detained in South Texas after a "three-month odyssey through 13 countries - from his homeland of Nepal through South Asia, Brazil, Mexico, and finally into Texas - show[ing] the way in which dangerous new strains of the disease can migrate across the world unchecked."
The COVID-19 pandemic shows no signs of abating, with outbreaks in many spots still occurring across the world. From the start, health organizations and governments were focused on implementing non-pharmaceutical interventions (NPIs) in the absence of any effective antivirals or vaccines.
On the one-year anniversary of the launch of the Global Alliance for Clean Cookstoves, the U.S. made an additional financial commitment of up to $55 million, "bringing the total United States commitment to up to $105 million in the first five years," according to a State Department press release.
Direct-to-consumer advertising (DTCA) for a commonly prescribed antiplatelet drug does not appear associated with increased use, but may be associated with increased drug costs and Medicaid pharmacy expenditures, according to a report in the November 23 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem's Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS' proprietary EB66® cell line.
› Verified 4 days ago
Dr. Robert Joel Bush, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 750 N Freedom Blvd Ste 300, Provo, UT 84601 Phone: 801-852-1443 | |
Janee Namealoha Sells, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 3200 N Canyon Rd Ste C, Provo, UT 84604 Phone: 385-375-8724 | |
Dr. Marlin L Christianson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 475 West 940 North, Provo, UT 84604 Phone: 801-357-7930 Fax: 801-357-7014 | |
Tyson Schwab, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 395 W Bulldog Blvd Ste 205, Provo, UT 84604 Phone: 801-357-1770 | |
Mr. Gregory Lawrence Nielsen, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1750 N Wymount Terrace Dr, Provo, UT 84604 Phone: 801-422-2771 Fax: 801-422-0761 | |
Mr. Tyler Jason Fieldsted, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 475 W 940 N, Provo, UT 84604 Phone: 801-357-7926 Fax: 801-357-7927 | |
Dr. Matthew Craig Evans, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1157 N 300 W, #201, Provo, UT 84604 Phone: 801-581-2000 |